Drugs / OM-85
OM-85
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05857930 | Jun 2023 → Sep 2026 overdue | bronchial disorder | OM Pharma SA | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04496245 | Aug 2020 → Jun 2021 | COVID-19, viral respiratory tract infection | The University of Queensland | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06655272 | Feb 2025 → Jan 2026 overdue | respiratory tract infectious disorder | Campus-Bio-Medico University | Recruiting | No outcome recorded |
| Phase 4 | NCT07178002 | Dec 2024 → Jan 2026 overdue | respiratory tract infectious disorder | Fondazione Policlinico Universitario Campus Bio-Medico | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05677763 | Dec 2022 → Mar 2026 overdue | lower respiratory tract disorder, respiratory tract infectious disorder | OM Pharma SA | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01968421 | Mar 2015 → Nov 2018 | bronchiectasis | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03243565 Comparator | Nov 2017 → May 2019 | adenoid hypertrophy, respiratory tract infectious disorder | Dr. Sami Ulus Children's Hospital | Unknown | No outcome recorded |
Press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | OM Pharma SA | OM Pharma and SPH Keyuan Trade advance Broncho-Vaxom® (OM-85) availability across China ompharma.com ↗ |
| 2024-07-25 | OM Pharma SA | First Participant Dosed in Phase 1a/1b Clinical Trial Evaluating Safety and Tolerability of OM-85-In ompharma.com ↗ |
| 2022-07-27 | OM Pharma SA | In-silico identification of predictive biomarkers of response of OM-85 bacterial extract in Atopic Dermatitis ompharma.com ↗ |
| 2021-12-01 | OM Pharma SA | The bacterial extract OM-85 reduces the binding of SARS-CoV-2 on human bronchial epithelial cells ompharma.com ↗ |
| 2021-11-15 | OM Pharma SA | The bacterial extract OM-85 trains innate immune system and decreases betacoronavirus viral load in an in-vivo model ompharma.com ↗ |
| 2021-11-01 | OM Pharma SA | The bacterial extract OM-85 is decreasing in vitro SARS-CoV-2 viral infection in epithelial cells ompharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OM-85 | “OM 85 (lyophilized bacterial lysate) proved effective in increasing the immune response against bacteria in animal models.” NCT06655272 ↗6“OM 85 (lyophilized bacterial lysate) proved effective in increasing the immune response against bacteria in animal models.” NCT07178002 ↗ “Broncho-Vaxom adult capsules® (OM85)” NCT04496245 ↗ |
| Known as | OM-85 BV | “Drug: OM-85 BV” NCT01968421 ↗ |
| Known as | Vaxoral | “Effect of Vaxoral® (OM-85) on Frequency of Respiratory Tract Infections and Size of Adenoid Tissue in Preschool Children With Adenoid Hypertrophy” NCT03243565 ↗ |
| Modality | Other / unclassified | “OM-85, consisting of extracts of eight kinds of bacteria important in respiratory infections, could support the respiratory tract resistance to the pathogens.” PMID 24773830 ↗ Apr 2014 |
| Route | Oral | “The treatment dose of OM-85 will be one daily capsule taken orally for 10 days each month for 3 consecutive months at the beginning of the study” PMID 24773830 ↗ Apr 2014 |